Author: Hongshuo Shi1, Ting Liu2, Chengda Dong1, Kun Zhen1, Yuxuan Wang1, Pengjun Liu1, Guomin Si2, Lei Wang3, Min Wang1
Affiliation:
1 Shandong University of Traditional Chinese Medicine, Jinan, China.
2 Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
3 The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Conference/Journal: Biomed Res Int
Date published: 2022 Aug 2
Other:
Volume ID: 2022 , Pages: 7728973 , Special Notes: doi: 10.1155/2022/7728973. , Word Count: 242
Background:
As a traditional Chinese exercise, Qigong has potential benefits for the management of chronic obstructive pulmonary disease (COPD). This overview is aimed at assessing the existing evidence for the intervention of Qigong in COPD so as to provide scientific guidance for clinical decision-making.
Methods:
The systematic reviews (SRs)/meta-analyses (MAs) of Qigong for the treatment of COPD were obtained from 7 electronic databases with the search date set at April 5, 2022. Two researchers independently assessed the methodological quality, reporting quality, and evidence quality for the included SRs/MAs using the following tools: the Assessment of Multiple Systematic Reviews 2 (AMSTAR-2), the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 (PRISMA 2020), and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system.
Results:
A total of 13 SRs/MAs were included in this overview. All SRs/MAs assessed by AMSTAR-2 had more than one critical defect, so all SR/MAs were rated very low. Regarding the assessment of reporting quality, the results of PRISMA 2020 showed that none of the SRs/MAs were fully reported. In addition, the results of the GRADE assessment of the quality of evidence indicated that only 3 outcomes were rated as high quality across all SRs/MAs.
Conclusion:
Current evidence suggests that Qigong is effective and safe for the management of patients with COPD. However, the high risk of bias in the original clinical studies and the low quality of the SRs/MAs reduced the reliability of the results.
PMID: 35958822 PMCID: PMC9363203 DOI: 10.1155/2022/7728973